Dahlia (Dahlia pinnata Cav.): A Comprehensive Reference on Its Identity, Phytochemistry, Traditional Use, and Scientific Evidence as a Dietary Supplement and Functional Ingredient
1. Identity and Botanical Classification
1.1 Scientific Nomenclature and Taxonomy
Dahlia belongs to the Asteraceae family, which includes other well-known flowering plants such as sunflowers, chrysanthemums, and zinnias. The primary species used in dietary supplement and functional food contexts is Dahlia pinnata Cav., a cultivar whose synonym is Dahlia variabilis Desf., as recognized in The World Flora Online. The plant is named after Swedish botanist Anders Dahl: the director of the Royal Botanic Garden in Madrid, Abbé José Cavanilles, assisted by botanist Dr. Anders Dahl, began hybridizing the newly arrived plant; having classified the genus, Cavanilles named the first species for his Swedish friend, publishing a description of the first species, now named Dahlia pinnata.
It is native to Mexico and was one of the many plants cultivated by the ancient Aztecs, who valued it for its beauty and medicinal properties. With more than 40 different species within Mexico's borders, dahlias reflect the country's biodiversity. In 1963, Mexico formally declared Dahlia pinnata its national flower — a recognition of a connection that ran back centuries.
1.2 Natural Sources and Plant Parts Used
Two distinct plant parts of Dahlia pinnata are relevant to its use as a dietary supplement or functional ingredient: the tuberous roots (tubers) and the flower petals. These contain different primary bioactive compounds and have been studied for different purposes.
- Tubers: Dahlia (Dahlia pinnata) tubers have gained increasing attention as a source of inulin, a naturally occurring fructan-type polysaccharide, alongside chicory roots (Cichorium intybus) and Jerusalem artichoke (Helianthus tuberosus).
- Flower petals: The flowers contain biologically active substances such as flavonoids, hydroxycinnamic acids, organic acids, and inulin; among these substances, anthocyanins are especially noteworthy.
It is possible that all dahlia species are edible, but there is a clear record of human use of two particular species: the common garden dahlia (D. × pinnata or D. variabilis) and D. coccinea.
1.3 Common Forms and Preparations
Dahlia-derived ingredients appear in several forms on the market and in research:
- Inulin powder extracted from tubers: Inulin is isolated from fresh or dried dahlia tubers; the tubers are blanched, sliced, blended in hot water, and the inulin extract is evaporated and precipitated by 95% ethanol for 24 hours at room temperature, then separated and dried at 50 °C for 24 hours.
- Enzyme-assisted extracts: Enzyme-assisted extraction (EAE) methods have been applied for obtaining inulin from dahlia tubers, including physicochemical characterization and assessment of prebiotic activity.
- Petal (flower) extracts: Extracts and purified flavonoids are prepared from dahlia petals; HPLC analyses can show the flavonoid composition, and butein, sulfuretin, and isoliquiritigenin were found to be stable in an ethanol extract of dahlia petals when stored at −18 °C for at least 3 years, and in capsules stored for at least 6 months.
- Proprietary standardized extracts: A commercial extract designated Dahlia4™ — described as a flower and petal extract of Dahlia pinnata — is available in encapsulated dietary supplement formulations.
- Functional food ingredients: Inulin-type prebiotics from dahlia are used as functional food ingredients in beverages, yogurts, biscuits, and spreads, as well as dietary supplements.
2. Traditional and Historical Use
2.1 Pre-Columbian Mesoamerica and the Aztecs
The dahlia (Dahlia pinnata) has a rich history dating back to pre-Columbian times in Mexico. The indigenous people of Mexico, such as the Aztecs, are believed to have grown and used dahlia plants for medicinal, food, and decorative purposes.
The Aztec names for the plant reflect its practical uses. The dahlia has been known in Nahuatl as "Acocotli" and "Cocoxochitl," which roughly translates to "water cane," in reference to the dahlia's hollow stems and its use by the Aztecs as a water conduit. Another Nahuatl name, Chichipatli, means "bitter medicine."
The Aztecs used the tubers of Dahlia pinnata as a source of food and as a treatment for various ailments. Native people used the plant as a tonic diuretic, to treat cough, against colic, and to reduce fever. The tubers have the medicinal property of reducing glucose levels by producing inulin. The Aztecs also used dahlias for their medicinal properties; the long tuberous roots were cultivated and used to treat epilepsy.
The plants were used in religious ceremonies, traditional healers made them into medicine to treat a variety of physical ailments, and the Aztecs also ate the dahlia tubers as food.
Scholarly assessment of the historical record is cautious, however. Much is made in the popular literature of the dahlia's early application in herbal medicine, in which the Aztecs had developed considerable skill and a wealth of treatments. The Badianus Manuscript — written in 1552 to help apply local medical remedies to the native population, richly illustrated with Aztec-style drawings — depicts 204 plants, none of which can clearly be claimed for the dahlia.
2.2 Introduction to Europe and Early Functional Recognition
With Spanish colonization, seeds from dahlias were sent back to Europe to be cultivated. Dahlia tubers contain inulin, a natural fibre that was extracted before 1922 and used in the management of diabetes. The dahlia's role as an early industrial source of inulin preceded the widespread use of chicory root for this purpose.
Dahlia flowers have also been used to produce a yellow or orange dye used in traditional Mexican textiles. In Mexico, dahlia flowers are commonly consumed in different types of dishes.
3. Key Constituents and Active Compounds
3.1 Inulin-Type Fructans (Tuber)
The most extensively studied constituent from dahlia tubers is inulin. Inulin is a polysaccharide composed of fructose molecules linked through β(2–1) d-fructofuranoside bonds. This bond structure makes inulin resistant to digestion by digestive enzymes, leading to delayed gastric emptying and slowing of glucose absorption.
Structurally, inulin-type fructans consist of fructose units linked by β-(2→1) glycosidic bonds, which resist hydrolysis by human digestive enzymes in the upper gastrointestinal tract.
Dahlia tubers are among the richest plant sources of inulin. Inulin can be isolated from dahlia tubers at a content of 18.60 ± 4.45% and a carbohydrate content of 61.75 ± 0.75%. In another analysis, dahlia tuber from Bukittinggi City, West Sumatra, was reported to contain 84.08% inulin. The variability in inulin content is significant: the content of inulin varies significantly between different plants, both in quantity and type, influenced not only by the plant species but by the plant's growth location, environmental conditions, and other factors.
Enzyme-assisted extraction can achieve a high degree of purity: the highest yield achieved was 8.28% (wet basis), and the degree of purity of inulin was high (>90%) due to the physicochemical characteristics of the dahlia tuber; this inulin extract contains 2.31 ± 0.04% uronic acids, total phenols at 38.38 ± 0.18 μg CAE/g, and primary amino compound at 67.85 ± 1.15 μg/g dry sample.
3.2 Flavonoids and Chalcones (Flower Petal)
The petals of Dahlia pinnata contain a distinct and scientifically important profile of polyphenolic compounds:
- Butein (a chalcone): Butein is a rare chalcone that has been shown to regulate glucose homeostasis via inhibition of the nuclear factor kappa-B kinase subunit beta (IKKβ)/nuclear factor kappa B (NF-κB) pathway in the brain; the nontoxic plant Dahlia pinnata was investigated as a cultivatable source of butein as a potential treatment for type 2 diabetes.
- Sulfuretin (an aurone): Sulfuretin was purified from the dahlia extract as it was not commercially available (purity >98% by HPLC and 1H NMR analysis).
- Isoliquiritigenin (a chalcone): Identified in HPLC analyses of D. pinnata petal extract as a third key glucoregulatory compound.
- Kaempferol: Among tropical flowers studied for bioactive phenolics, kaempferol was the main phenolic identified in Dahlia pinnata, measured at 8,236 mg/100 g DW.
3.3 Anthocyanins (Flower Petal)
The food industry has focused on the search for potential sources of anthocyanins to replace synthetic dyes while providing health benefits; Dahlia pinnata has been proposed as a potential source of anthocyanins. The dahlia is a native, annual flower from Mexico with a wide diversity of shapes and colors; the ancestral use of the flower in several dishes and the intense color of the dark varieties make it a suitable candidate as a source of anthocyanins.
The anthocyanin profile of purified extracts of D. pinnata contains four main anthocyanins: delphinidin-3-glucoside, delphinidin-3-rutinoside, pelargonidin-3-sambubioside-5-glucoside, and peonidin-3-sambubioside-5-glucoside, the last two being uncommon as major anthocyanin components in other plant sources.
These water-soluble vacuolar pigments of a glycoside nature have significant health benefits, including antioxidant, antidiabetic, hypocholesterolemic, anticancer, cardioprotective, and hypotensive properties.
Dahlia pinnata flowers have a proximate composition similar to other important edible flowers with a high level of moisture (87%–92%) and fiber (6%–7%); the antioxidant activity of purified extracts was considerable (2.6–12 g/ml) compared to other sources of anthocyanins.
3.4 Additional Phenolic Compounds
Proximate composition, minerals, vitamin C, phenolic compounds, total anthocyanins, carotenoids, and antioxidant activity of dahlia flowers have been studied. In general, the highest values for phenolic compounds, anthocyanins, and antioxidant capacity were found in the purple dahlia; the type and concentration of phenolic compounds varied according to the color of the flower. The highest phenolic compound value was for hesperidin (398.9 mg·g−1), while the most detected phenolic compounds in the flowers were gallic and caffeic acids.
Dahlia plants also contain hydroxycinnamic acids and organic acids as biologically active substances.
3.5 Other Nutrients (Tuber)
Analysis of dahlia tuber flour shows approximately 80.8% water content, 0.36% ash content, 0.33% total fat content, 1.29% crude fiber content, 1.15% protein content, and 14.6% carbohydrate content. Dahlia tubers contain high carbohydrates and low fat content, with crude fiber and protein that can be used as low-calorie foodstuffs.
4. Mechanisms of Action
4.1 Inulin: Prebiotic Fermentation and Gut Microbiota Modulation
The term "inulin" is often used broadly to encompass all inulin-type fructans that selectively nourish beneficial intestinal microbiota, thus promoting host health. The primary mechanism is resistance to upper-GI digestion followed by selective colonic fermentation:
- Inulin-FOS is not digested by human enzymes and functions in a manner similar to soluble fiber; inulin also promotes the growth of beneficial intestinal bacteria, in particular bifidobacteria.
- Inulin, as a natural prebiotic that cannot be digested, stimulates the growth of beneficial bacteria such as Lactobacillus, which is useful for inducing the production of short-chain fatty acids (SCFAs) in the colon; this will reduce inflammation in the intestinal mucosa.
- Prebiotic activity assessment of dahlia-derived inulin found production of 7.69 ± 0.02 and 7.55 ± 0.04 μg CO₂-C/g/h for Lactobacillus plantarum and Bifidobacterium lactis, respectively.
Prebiotics' health benefits have been linked to microbiome–host complex interactions, modulating microbiota homeostasis, the gut–brain axis, microbiota–immune system crosstalk, and the intestinal barrier function.
4.2 Inulin: Glycemic Modulation
The β(2–1) d-fructofuranoside bond structure of inulin makes it resistant to digestion by digestive enzymes, leading to delayed gastric emptying and slowing of glucose absorption. In experimental models, administration of inulin from dahlia tubers significantly reduced serum glucose concentrations in diabetic rats. Notably, inulin extracts at doses of 1 g/kgBW and 1.5 g/kgBW showed a significant reduction in insulitis and HOMA-IR index in diabetic rats, while the 0.5 g/kgBW dose reduced insulitis without affecting HOMA-IR; inulin extract administration did not affect insulin expression in serum or pancreatic tissue.
A separate rat study on fatty liver showed that the T2DM group had a significantly higher percentage of fatty liver compared to controls, but compared to the T2DM group, there was a decrease in the percentage of fatty liver in the groups given dahlia inulin at all doses tested.
4.3 Petal Chalcones: Central Insulin Signaling and Hypothalamic Anti-inflammation
The mechanism identified for the flower petal flavonoid complex is distinct and operates centrally — via the brain — rather than through pancreatic insulin secretion:
- The glucose-regulating effect of the extract was not mediated by butein alone but by butein combined with the closely related flavonoids sulfuretin and/or isoliquiritigenin; mechanistically, the extract improved systemic insulin tolerance.
- Inhibition of phosphatidylinositol 3-kinase to block insulin signaling in the brain abrogated the glucoregulatory effect of the orally administered extract; the extract reinstated central insulin signaling and normalized astrogliosis in the hypothalamus of high-fat diet-fed mice; using NF-κB reporter zebrafish to determine IKKβ/NF-κB activity, a potent anti-inflammatory action of the extract was found.
- The glucoregulatory effect of the extract is dependent on central PI3K, a key component in insulin signaling; the improvement in glucose tolerance is associated with an anti-inflammatory effect of the dahlia extract and increased insulin signaling in the hypothalamus, the major glucoregulatory region of the brain.
4.4 Inulin: Calcium and Mineral Absorption
Inulin has significant functions such as improving calcium absorption through passive diffusion, bolstering calcium absorption via ion exchange, and expanding the absorption surface of the colon by stimulating cell growth; it also boosts calcium absorption by increasing calcium solubility, stimulating levels of calcium-binding protein expression, and increasing useful microorganisms. It increases calbindin levels and stimulates transcellular active calcium transport.
5. Scientific Evidence by Area of Use
5.1 Blood Glucose Regulation and Type 2 Diabetes
5.1.1 Flower Petal Extract — Human Clinical Evidence (Strongest)
The most significant clinical study was published in Life Metabolism (Oxford University Press) in 2023 by Pretz et al. from the University of Otago, New Zealand. A randomized controlled crossover clinical trial on participants with prediabetes or T2D confirmed the safety and efficacy of the extract in humans; the researchers identified an extract from the flower petals of D. pinnata as a novel treatment option for T2D, potentially targeting the central regulation of glucose homeostasis as a root cause of the disease.
A clinical trial involving 13 people with diabetes and prediabetes showed the dahlia extract was effective at managing blood sugar. The extract (at doses of 15, 30, or 60 mg/m²) was given 1 hour before a glucose tolerance test (GTT); GTT and AUC results for participants with established T2D (HbA1c >48 mmol/mol) were assessed; liver function, full blood count, and renal function were unchanged by treatment with the dahlia extract.
The authors describe this as a "first in human" clinical study on the dahlia extract in people with prediabetes and T2D that confirmed its promising glucose-lowering action.
Evidence strength: This is a small (n=13), single-center, crossover randomized controlled trial — the highest study design tier but with a very small sample size. It provides proof-of-concept evidence in humans, but larger, longer-duration, placebo-controlled trials are needed before efficacy conclusions can be generalized.
5.1.2 Flower Petal Extract — Animal Evidence
In mice fed a high-fat diet (HFD) to induce glucose intolerance, an oral D. pinnata petal extract improved glucose tolerance at doses of 3.3 mg/kg body weight and 10 mg/kg body weight. Chronic treatment with dahlia extract did not affect liver morphology, liver fat content, or weight, indicating its potential for long-term glucose homeostasis.
5.1.3 Tuber Inulin — Animal Evidence
A 2024 study examined the effect of inulin from dahlia tuber extract on blood glucose levels, serum insulin expression, pancreatic tissue insulin expression, HOMA-IR, and the extent of insulitis in diabetic rats. In this experimental study, 20 male Wistar rats were randomly allocated to five groups; Groups III, IV, and V were streptozotocin-induced diabetic groups treated with inulin at doses of 0.5 g/kgBW, 1.0 g/kgBW, and 1.5 g/kgBW, respectively, with the inulin administered for 21 days.
Administration of inulin from dahlia tubers significantly reduced serum glucose concentrations in diabetic rats; only inulin extracts at doses of 1 g/kgBW and 1.5 g/kgBW showed a significant reduction in insulitis and HOMA-IR index in diabetic rats, while the 0.5 g/kgBW extract reduced insulitis without affecting HOMA-IR. Inulin extract administration did not affect insulin expression in serum or pancreatic tissue. Inulin from dahlia tuber was concluded to exert antidiabetic properties by improving insulin resistance and insulitis.
Roshanravan's research in 2017 showed that administration of 10 g/day of inulin supplementation alone could not improve fasting plasma glucose, insulin, HbA1c, and HOMA-IR in type 2 DM patients, but results were better when using inulin with a butyrate supplement.
Evidence strength (inulin, glycemia): Animal evidence is positive but mixed in human trials. The dahlia-specific inulin data are primarily animal-based. The broader inulin literature in humans shows modest, inconsistent effects on glycemic markers.
5.2 Gut Health and Prebiotic Activity
Several animal and human studies have shown inulin to function as a prebiotic, in promoting good digestive health, influencing lipid metabolism, and decreasing risk of osteoporosis by increasing calcium absorption.
An in vitro study specifically on dahlia tuber inulin found: when grown in inulin-containing and inulin-extract media, the prebiotic index (PI) was 4.3 and 4.7, respectively, compared to a PI of 1.1 for MRS media alone. The high prebiotic index indicated a larger probiotic population of L. casei AP than that of Enterobacteriaceae/pathogen (E. coli) when co-cultured in the same growth medium, suggesting that L. casei AP has a higher capability to consume inulin than E. coli does.
A previous study reported that the inulin from dahlia tubers is of better quality due to the presence of soluble and insoluble fibers; due to its potential, inulin from dahlia tubers has been increasingly tested for its capability as a prebiotic.
Evidence strength: Prebiotic activity is well-established for inulin-type fructans broadly; in vitro data for dahlia-specific inulin are supportive, but controlled human trials using dahlia tuber inulin for gut health endpoints specifically are lacking.
5.3 Antioxidant Activity
Dahlia pinnata flowers have been analyzed for antioxidant activity using the DPPH method; results showed flowers with a proximate composition similar to other edible flowers, with a high level of moisture (87%–92%) and fiber (6%–7%); the antioxidant activity of purified extracts was considerable (2.6–12 g/ml) compared to other sources of anthocyanins.
FOS consumption is known to confer health benefits including antioxidant properties, favourable dietary modulation of the human colonic microbiota, and immunomodulatory effects.
Evidence strength: Antioxidant activity of dahlia extracts has been demonstrated in in vitro assays; this does not directly translate to in vivo antioxidant effects. No human clinical trials on dahlia-specific antioxidant endpoints have been located.
5.4 Lipid Metabolism
Dahlia tubers are rich in inulin-type fructans and polyphenols, both of which have demonstrated beneficial effects on blood glucose and lipid metabolism. FOS consumption has also been associated with a lowering effect on serum lipid and cholesterol concentration.
Rat studies using dahlia tuber inulin as a creamer constituent have examined effects on lipid profiles and liver histopathology. Research aimed to analyze dahlia tuber inulin creamer and the effect of its administration on lipid profiles, liver function, and liver histopathology in rats; a total of sixteen male rats aged 2–3 months old and weighing 150–200 grams were divided into four categories.
Evidence strength: Effects on lipid parameters are supported by the broader inulin/FOS human literature; dahlia-specific human data on lipids are not yet available from the identified sources.
5.5 Calcium Absorption and Bone Health
An inulin intake of at least 8–10 g/day supports calcium absorption and total body bone mineral content/density in adolescents through known mechanisms of action; it also significantly enhances calcium absorption and improves bone health in postmenopausal women and adult men.
While there is conclusive evidence of the benefits of inulin in rat models, results in human trials differ; these differences may result from variations in dosage and duration of inulin intake. The dose administered in rat models is usually around 10 g/kg/day, whereas the dose in humans usually corresponds to less than 0.3 g/kg/day. As a result, the impact of low dosage on mineral absorption is minimal in human trials.
Evidence strength: These findings apply to the class of inulin-type fructans generally. No specific human bone-health studies on dahlia-sourced inulin were identified.
5.6 Hypothalamic Inflammation
The yellow dahlia flower extract, or isolated yellow flavonoids in certain combinations, can restore glucoregulation in mice fed a high-fat diet; in humans, the dahlia extract improved glucoregulation in people with prediabetes and T2D. The glucoregulatory effect of the extract is dependent on central PI3K, a key component of insulin signaling; the improvement in glucose tolerance is associated with an anti-inflammatory effect of the dahlia extract and increased insulin signaling in the hypothalamus, the major glucoregulatory region of the brain.
Evidence strength: Mechanistic evidence from animal and zebrafish models is robust; confirmation of the same central mechanism operating in the human clinical trial remains to be fully established in larger studies.
5.7 Anthocyanin-Related Health Properties (Emerging)
Anthocyanins from dahlia flowers are considered water-soluble vacuolar pigments of a glycoside nature, reported to have significant health benefits including antioxidant, antidiabetic, hypocholesterolemic, anticancer, cardioprotective, and hypotensive properties. These attributions are based on the known biology of the identified anthocyanin classes and their in vitro properties; no specific human clinical trials on dahlia flower anthocyanins for these endpoints were identified in the literature search.
6. Body Systems and Health Areas Associated with Dahlia
- Gastrointestinal system: Prebiotic modulation of gut microbiota via inulin; stimulation of Lactobacillus and Bifidobacterium species; production of short-chain fatty acids; reduction of colonic inflammation.
- Endocrine/Metabolic system: Modulation of blood glucose, insulin sensitivity, and HOMA-IR through both inulin (peripheral/gut-mediated) and flavonoid-chalcone extract (central, brain-mediated).
- Central nervous system / Neuroendocrinology: Hypothalamic insulin signaling and reduction of hypothalamic neuroinflammation via IKKβ/NF-κB pathway inhibition.
- Cardiovascular/Lipid system: Inulin-type fructans are associated in the broader literature with modest improvements in serum lipids and cholesterol; specific dahlia data are preliminary.
- Musculoskeletal system (bone): Inulin-class fructans support calcium absorption, with demonstrated effects on bone mineral density in adolescents and postmenopausal women.
- Immune system: Inulin is associated with immunomodulatory effects through microbiota–immune crosstalk; NF-κB pathway inhibition by flower flavonoids contributes an additional anti-inflammatory dimension.
7. Dosage Forms and Dosages Reported in Studies
7.1 Flower Petal Extract (Human Clinical Trial)
In the 2023 randomized controlled crossover clinical trial (n=13, participants with prediabetes or T2D), the extract was administered at doses of 15, 30, or 60 mg/m² body surface area, given 1 hour before a glucose tolerance test; GTT and AUC results were assessed for participants (n=5) with established T2D (HbA1c >48 mmol/mol).
7.2 Flower Petal Extract (Animal Studies)
In high-fat-diet-fed mice, an oral D. pinnata petal extract improved glucose tolerance at doses of 3.3 mg/kg body weight and 10 mg/kg body weight.
7.3 Tuber Inulin (Animal Studies)
In a 2024 experimental study using 20 male Wistar rats, the groups were treated with inulin at doses of 0.5 g/kgBW, 1.0 g/kgBW, and 1.5 g/kgBW; the inulin was administered for 21 days. In a related study on diabetic rats, administration of inulin from dahlia tuber extract at a dose of 1.5 mg/g body weight could significantly reduce blood glucose levels and body weight in diabetic rats.
7.4 Tuber Inulin (Human Inulin Literature — General)
In studies regarding the daily tolerance dosage of inulin, a 20 g/day intake of inulin with an average degree of polymerization (DP) of 9 caused only minor gastrointestinal side effects such as gas and bloating. An inulin intake of at least 8–10 g/day is associated with support of calcium absorption and total body bone mineral content/density in adolescents.
Roshanravan (2017) found that 10 g/day of inulin supplementation alone could not improve fasting plasma glucose, insulin, HbA1c, and HOMA-IR in type 2 DM patients.
These human dosages were derived from clinical trials using inulin generally (predominantly chicory-sourced); specific human dosage trials for dahlia tuber inulin have not been identified in the searched literature.
8. Safety Considerations and Interactions
8.1 Gastrointestinal Tolerance of Inulin
The most common side effects of inulin include gastrointestinal symptoms such as flatulence, bloating, abdominal distension, loose stools, and increased stool frequency; these symptoms have been more frequently reported with inulin doses in the range of 15 to 30 g per day than with lower doses.
8.2 Liver, Renal, and Hematological Safety (Flower Extract)
In the clinical trial of dahlia flower petal extract in people with prediabetes and T2D, liver function, full blood count, and renal function were unchanged by treatment with the dahlia extract.
8.3 Long-Term Safety (Animal, Flower Extract)
Chronic treatment with dahlia extract did not affect liver morphology, liver fat content, or weight in animal studies, indicating its potential for long-term glucose homeostasis.
8.4 Stability of Active Compounds
HPLC analysis confirmed that butein, sulfuretin, and isoliquiritigenin were stable in an ethanol extract of dahlia petals when stored at −18 °C for at least 3 years and in capsules stored for at least 6 months.
8.5 Asteraceae Allergy Cross-Reactivity
Dahlia pinnata belongs to the Asteraceae family, which includes other well-known flowers such as sunflowers, chrysanthemums, and zinnias. Individuals with known hypersensitivity to other Asteraceae plants (e.g., ragweed, chamomile, echinacea) may carry an elevated risk of cross-reactive allergic responses to dahlia-derived preparations, though no specific human adverse event studies on this were identified in the literature search.
8.6 Variability in Composition
The content of inulin varies significantly between different plants, both in terms of quantity and type; this variability is influenced not only by the plant species but by the plant's growth location, environmental conditions, and other factors. Even plants of the same species grown in different locations or environments can produce distinct bioactive compounds or compounds from the same group with varying levels of bioactivity. This has direct implications for the consistency and standardization of dahlia-derived supplements.
8.7 Current Regulatory and Evidence Context
No monographs from the European Medicines Agency (EMA), WHO, Commission E, ESCOP, or European Pharmacopoeia specifically for Dahlia pinnata as a medicinal plant were identified in the literature search. The ingredient is not listed in the NIH Office of Dietary Supplements fact sheet database as a standalone supplement. Human clinical evidence is currently limited to a single small-scale randomized controlled crossover trial for the petal extract and general inulin-class literature for the tuber; the body of evidence for dahlia-specific preparations is therefore at an early, preliminary stage.
References
Go back